Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective
EGPA Review
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read Article
Chronic Low Back Pain Disappointments in a Randomized Trial
Annals of Internal Medicine reports that patients with chronic low back pain (cLBP) may benefit from physical therapy (PT); but when that fails, other secondary measures (cognitive behavioral therapy (CBT) or https://t.co/17JObbXz5U
Dr. John Cush @RheumNow( View Tweet )
Vitamin D in Rheumatic Disease - Is It Good Enough?
Vitamin D in rheumatic disease — is it sufficient? Vitamin D deficiency/insufficiency is common and linked to inflammatory rheumatic diseases, raising the question of whether low vitamin D drives immune dysregulation, disease https://t.co/CLBFii2TbR
Dr. John Cush @RheumNow( View Tweet )
🚨 SAVE THE DATE
June 3–6, 2026
RheumNow is bringing you real-time coverage of #EULAR2026
👉 Breaking data
👉 Late-breakers
👉 Global expert insights
Don’t miss a moment. #Rheumatology https://t.co/hqmIdeoS4H
Dr. John Cush @RheumNow( View Tweet )
APR: Still's Disease
Companion slide deck for the Advanced Practice Rheum: Still's Disease and Fever video, featuring Dr. Jack Cush.
https://t.co/wsUP2zEulC https://t.co/AWSNt9Uzlg
Dr. John Cush @RheumNow( View Tweet )
Influential Rheumatoid Factors (5.8.2026)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/BaugLQEIai https://t.co/WdWXAfB5lk
Dr. John Cush @RheumNow( View Tweet )
Toll-Like Receptor Drugs Effective in Cutaneous Lupus
MedPage Today
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
Read Article
Parvovirus B19 Infection - Images from JAMA Dermatology. 40yoM 2-days asymptomatic rash w/ fever to 39°C, w/ arthralgias, Rash on BL cheeks, inguinal, flanks, axilla. WBC =2K, CRP 1.24 mg/dl. Dx by PCR for parvovirus B19 DNA https://t.co/LGGnabvFvA https://t.co/yyBF9pEGls
Links:
Dr. John Cush @RheumNow( View Tweet )
Dr. Robert Terkeltaub walks through the evolution of gout at #RheumNowLive 2026.
🎧 Listen here: https://t.co/S6RXQo2Umt
#Gout #Rheumatology #MedEd https://t.co/XDbTmj3MOw
Dr. John Cush @RheumNow( View Tweet )
Chronic Low Back Pain Disappointments in a Randomized Trial
Annals of Internal Medicine reports that patients with chronic low back pain (cLBP) may benefit from physical therapy (PT); but when that fails, other secondary measures (cognitive behavioral therapy (CBT) or mindfulness) may not be effective.
Read Article
Vitamin D in Rheumatic Disease - is it Good Enough?
Vitamin D deficiency or insufficiency of is highly prevalent and has been often associated with inflammatory rheumatic diseases, raising the question of whether inadequate vitamin D status contributes to immune dysregulation, incipient disease, increased disease activity, or poor skeletal
Read Article
“60-40-20” - Ed Keystone
(rumor has it he was actually bidding on a copy of my textbook!)
Dr. John Cush @RheumNow( View Tweet )
In Still's disease, what is the primary life-threatening complication clinicians must monitor for? If you think you know the answer, prove it in this week's RheumIQ quiz at https://t.co/KVK8J2iaFQ https://t.co/O62ZpIciWW
Dr. John Cush @RheumNow( View Tweet )
24 systemic amyloidosis pts (AA type 46%, AL 29%); 62% joint pain & AM stiff, axial 37.5%, macroglossia (4 pts, 17%), carpal tunnel (12%), proteinuria > 1 gm 50%, CKD 21%, Cardiac amyloid 29%. Amyloid was secondary to Rheum Dx in 11/24. Better survival w/ AA than AL (91% vs https://t.co/hwkpeav4MQ
Dr. John Cush @RheumNow( View Tweet )
Steroids
Corticosteroids remain a cornerstone of rheumatologic therapy — rapidly effective but chronically dangerous, as their power to suppress inflammation through inhibition of prostaglandins, lipoxygenase, pro-inflammatory cytokines, and proteases comes at the cost of a https://t.co/PKdnFi1XSr
Dr. John Cush @RheumNow( View Tweet )
Have a Rheumatology question or case for Jack Cush? Record it here, and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/yyGRvXx3lL https://t.co/MgPqpaFLOc
Dr. John Cush @RheumNow( View Tweet )
Influential Rheumatoid Factors (5.8.2026)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
Read Article
Review of Toll-like Receptor Research
A new review on TLRs systematically summarizes 40 years of discoveries in the TLR field, from the initial identification of Toll in Drosophila embryonic development to the current understanding of multilayered regulatory mechanisms that https://t.co/Rvy24nmuTj
Dr. John Cush @RheumNow( View Tweet )
Nurses - the calm through chaos
Nurses are a unique breed. When they appear, it’s always a blessing. But who goes into nursing? What kind of person choose nursing over doctoring?
https://t.co/smUWg06nVh https://t.co/swQYJ3NfZF
Dr. John Cush @RheumNow( View Tweet )
Supposedly there's a shortage of Infectious Dz specialists & Fellowship applic are down. Survey of 380 Int. Med residents (41 prgs) shows ID interest signif assoc w/ exposure to ID in Yr 1 & 2, outpt clinics, ID- research. https://t.co/AUkiIvsuaV https://t.co/pOqkBhy93U
Dr. John Cush @RheumNow( View Tweet )
A Patient’s Plea for a New Paradigm in Autoimmune Disease
A current article in Nature Reviews Rheumatology has a patient boldly asking why we rheumatologists aren't more like her oncologists?
https://t.co/fJMwR864HW https://t.co/a6CJPpo4yq
Dr. John Cush @RheumNow( View Tweet )
American Nurses Assoc. response to Dept of Education’s Final Rule on Graduate Loans for nurses: "..profoundly dismayed by DoE exclusion of nursing from....“professional degree” programs... this ignores the voices of over 245,000 nurses and nurse advocates https://t.co/WEYdiO9x4n https://t.co/3wxOwDBHVg
Dr. John Cush @RheumNow( View Tweet )
A Review of Hydroxychloroquine Ocular Toxicity
While hydroxychloroquine (HCQ) is thought to be a very safe drug, its ocular risk profile is probably more serious than appreciated. A comprehensive review published in the Journal of Rheumatology discusses HCQ pharmacokinetics, mechanisms of retinal toxicity, risk stratification, and evidence-
Read Article
More Comorbidity in Difficult-to-Treat RA
A systematic review demonstrated that smoking, obesity, fibromyalgia, and depression are significantly associated with difficult-to-treat rheumatoid arthritis (D2T-RA).
https://t.co/guMm6mqJGr https://t.co/xiykw5tBlJ
Dr. John Cush @RheumNow( View Tweet )
Therapeutic Updates
5-Year Results of an IL-23 Inhibitor in Patients With PsA
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.
Read Post
Poster Hall
Recent Blogs
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
ACR 2025 Daily Podcasts Day4a-
ACR 2025 Daily Podcasts Day3a
ACR 2025 CAR-T Topic Podcasts Compilation 1
